SCHEMBL16442152

SCHEMBL16442152

CCOC(=O)Cc1cn2ccc(OC)cc2n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.52
ALDH1A1 P00352 7/20 0.52
TDP1 Q9NUW8 3/20 0.52
POLB P06746 3/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
TP53 P04637 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.49
KMT2A Q03164 2/20 0.49
METTL3 Q86U44 3/20 0.48
MAPT P10636 6/20 0.47
PKM P14618 2/20 0.46
MAPK1 P28482 1/20 0.44
THRB P10828 1/20 0.43
FPR1 P21462 1/20 0.43
RAB9A P51151 1/20 0.43
HSD17B10 Q99714 1/20 0.43
CYP19A1 P11511 1/20 0.42
MAOB P27338 1/20 0.42
MEN1 O00255 1/20 0.42
ESR1 P03372 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15230641 0.86 KDM4E (0.71) KDM4EALDH1A1TDP1POLBL3MBTL1
SCHEMBL20985955 0.84 KDM4E (0.53) KDM4EALDH1A1TDP1POLBL3MBTL1
SCHEMBL14912238 0.84 KDM4E (0.53) KDM4EALDH1A1TDP1POLBL3MBTL1
SCHEMBL12618994 0.81 KDM4E (0.50) KDM4EALDH1A1TDP1POLBL3MBTL1
SCHEMBL26611293 0.81 KDM4E (0.50) KDM4EALDH1A1TDP1POLBL3MBTL1
SCHEMBL23639582 0.81 KDM4E (0.50) KDM4EALDH1A1TDP1POLBL3MBTL1
SCHEMBL13080337 0.80 METTL3 (0.49) KDM4EALDH1A1TDP1POLBL3MBTL1
SCHEMBL4352501 0.80 KDM4E (0.74) KDM4EALDH1A1POLBL3MBTL1TP53
SCHEMBL1668064 0.79 ALDH1A1 (0.60) KDM4EALDH1A1TDP1POLBL3MBTL1
SCHEMBL16424354 0.79 METTL3 (0.50) KDM4EALDH1A1TDP1POLBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150045551-A1 FUSED AZOLE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD (JP) 2015-02-12 US disclosed
EP-2832722-A1 FUSED AZOLE DERIVATIVE Taisho Pharmaceutical Co., Ltd. (JP) 2015-02-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150045551-A1 FUSED AZOLE DERIVATIVE AVPR1B, AVPR1A, GRIN2B KDM4E 1678/4885ALDH1A1 1108/4885TDP1 2420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.